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from many other descriptions of the
HRA assay. A lack of specificity also
has been seen with the autologous
serum skin test, which is another mea-
sure of ‘‘functional’’ autoantibodies in
CIU. The autologous serum skin test is
positive in up to 37% of non-CIU
subjects (Guttman-Yassky et al., 2007).
On a limited basis, HRA-positive CIU
subjects have been reported to have
more severe disease (Sabroe et al.,
2002) and to be more likely to have
thyroid autoantibodies (Kikuchi et al.,
2003) than HRA-negative subjects. How-
ever, skin biopsies show similar patho-
logy in HRA-positive versus HRA-
negative subjects with CIU (Sabroe
et al., 1999; Ying et al., 2002). More
importantly, in making decisions about
starting immunomodulatory medication
such as cyclosporine in CIU patients,
HRA measurement is not clearly needed,
because the presence of ‘‘functional’’
autoantibodies is not correlated to
clinical response (Morgan and Khan,
2008).
At the present time, available assays
for autoimmunity are flawed and do not
consistently assist clinicians in their
understanding of CIU’s pathogenesis.
What is truly needed is a reproducible
assay to advance the specific definition
of autoimmune urticaria.
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TO THE EDITOR
Basal cell carcinoma (BCC) is the most
common cancer in humans. Very often
patients are prone to develop multiple
lesions at different body sites (Rama-
chandran et al., 1999, 2001; and cited
therein; Heitzer et al., 2007). Recently,
several studies have been performed to
determine the clonal origin of BCC in
patients with multiple lesions (Walsh
et al., 1998; Saldanha et al., 2002;
Shulman et al., 2006). For instance,
Shulman et al. (2006) performed loss
of heterozygosity (LOH) analysis and
X-chromosome inactivation studies to
determine the clonal origin of multiple
BCCs from patients exhibiting lesions at
different anatomical locations. They
reported that in all BCCs displaying
LOH, the same allele was lost in multi-
ple tumors from a given patient. Further-
more, an identical X-chromosome
inactivation pattern was noted in certain
tumors. Hence, they suggested that the
majority of BCCs in an individual might
originate from one single tumor cell
clone, independent of the anatomical
site and time of lesion occurrence.
However, van Steensel and Frank
(2006) questioned the theory of mono-
clonality of multiple BCCs. They stated
that it is important to sequence the
PTCH gene to prove monoclonality of
multiple BCCs because PTCH mutations
are a hallmark of BCCs. If identical
PTCH mutations are present in distinct
BCCs at different anatomical locations
from individual patients with multiple
lesions, it would indicate monoclonal-
ity. If not, then it would suggest that
each tumor arises independently from a
distinct initiated (progenitor) cell.
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To address the question of clonality,
we sequenced the PTCH gene and
analyzed the LOH pattern of BCCs
from a total of six patients with multiple
lesions (three lesions from anatomically
distant locations per each patient),
using methods as described earlier
(Heitzer et al., 2007). The results of
the first BCC of each patient had been
reported in our earlier study (Heitzer
et al., 2007). All BCC samples were
obtained from patients of an epidemio-
logic investigation that had been ap-
proved by the Ethical Committee of the
Medical University of Graz, Austria.
Those patients who were still alive at
the time of the study gave informed
consent to DNA analysis of their tumor
samples. The study was conducted
adherent to the Declaration of Helsinki
Principles.
We detected a total of 18 differential
PTCH mutations in 14 of 18 BCCs
(Table 1). Most of the mutations bore
the UV fingerprint. Only in a single
case (patient A13) was an identical
PTCH mutation present in two of three
lesions. Comparison of normal and
tumor tissues revealed no LOH of the
entire PTCH allele in any of the tumors.
However, LOH was present at certain
single nucleotide polymorphism sites in
11 of 18 (61%) BCCs (Table 2). Im-
portantly, the pattern of single nucleo-
tide polymorphism loss differed among
multiple BCCs from the individual
patients. For example, in patient A13,
each of the three BCCs had a different
pattern of LOH. Similarly, a different
pattern of LOH was detected in multi-
ple tumors of other patients. Interest-
ingly, in six lesions (B1b, B1c, B2a,
Table 1. Patient characteristics and PTCH mutations in multiple BCCs
Patienta
(sex) Tumorb
Tumor
location
Age
(years)c LOHd
Presence of
mutation
Exon/intronic
position Codon
Codon
surrounding
sequencee
Base
change Strandf
Amino acid
change
Type of
mutationg
A13 (F) a Cheek 42 Yes Yes 5 237 cTTCc C-T NT Glu-Lys UV
b Parietal scalp 34 Yes Yes 11 504 gCCAt C-A T Pro-Gln Other
c Lower eyelid 48 Yes Yes 11 504 gCCAt C-A T Pro-Gln Other
B1 (M) a Preauricular 66 Yes Yes 15 816 cCAGc C-T T Gln-Stop UV
b Shoulder 66 No Yes 6 266 gGAAg G-T T Glu-Stop Other
c Upper arm 66 No Yes 9 417 tCAAa C-T T Gln-Stop UV
18 1039 cACAt A-T T Thr-Ser Other
B2 (F) a Forehead 75 No Yes 10 494 tTCCt C-T T Ser-Phe UV
1348IVS19 — ccccc C-T T — UV
1503IVS+68 — gccag C-T T — UV
b Calf 73 No Yes 21 1168 gCTGg C-T T none UV
c Retroauricular 79 No Yes 18 1010 cCCCa C-T T Pro-Leu UV
21 1167 gCCCa C-T NT Gly-Arg UV
B6 (M) a Nose 79 Yes Yes 3 159 gATAc A-T T Ile-Leu Other
b Preauricular 78 Yes No — — — — — — —
c Shoulder 78 Yes Yes 18 1018 cCCAg C-T NT Trp-Stop UV
B7 (F) a Nose 80 No Yes 2 115 aTCCc CC-TT NT Gly-Lys UV
b Abdomen 70 No No — — — — — — —
c Ear 70 Yes No — — — — — — —
B20 (M) a Shoulder 75 Yes Yes 12 576 cCAGg C-T T Gln-Stop UV
b Back 73 Yes No — — — — — — —
c Forearm 79 Yes Yes 747IVS1 — CTctg C-T NT — UV
BCC, basal cell carcinoma; F, female; M, male.
aPatients are described in Materials and Methods of Heitzer et al. (2007).
ba, BCC originally analyzed in Heitzer et al. (2007); b and c, BCC of the same patient at an anatomically different location analyzed in this study.
cAge at tumor appearance.
dFrom data presented in Table 2.
eThe sequence for the strand (transcribed or nontranscribed) containing a pyrimidine at the mutation site is shown in the 50-30 direction. Nucleotides of the
affected codon are written in capital letters. Mutated bases are shown in bold letters.
fStrand with affected pyrimidine: T, transcribed strand; NT, nontranscribed strand.
gUV, UV fingerprint; mutation types determined as described earlier in Heitzer et al. (2007).
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B2b, B2c, and B7a) from three patients,
PTCH mutations were found, but LOH
could not be detected. However, in
three BCCs (B6b, B7c, and B20b) from
three patients, LOH was found despite
the absence of PTCH mutations, sug-
gesting that allele dosage may have
contributed to tumor development
(Cunningham et al., 2006). In fact,
Cunningham et al. reported infrequent
p53 mutations compared to the high
frequency of LOH in tumors.
On the basis of our PTCH mutation
and LOH pattern results, we can con-
clude that BCCs in patients with multi-
ple lesions are most likely polyclonal in
origin. Only in one case (patient A13),
was an identical PTCH mutation pre-
sent in two lesions; however, this may
have happened by chance rather than
representing a true monoclonal origin
of these two lesions. Indeed, a permu-
tation test of the null hypothesis that
two identical mutations out of the 14
PTCH-mutated tumors are found in the
same patient by chance gave a P-value
of 0.055. The findings presented here
Table 2. Differences in SNP variants in PTCH-mutated BCCs and adjacent normal tissue
SNPc
Samplea
Sequence
difference Tissueb
1503IVS
+99C/T
1504IVS
51C/G 1665 T/C 1686 C/T
2560IVS
+9G/C
2561IVS
-80G/C
2887IVS
+21G/A 3944 C/T
A13n Yes N C/Td G/C T C/T G/C G G/A C/T
A13a T C/T G/C T C#### G/C G G/A C/T
A13b T C#### C#### T C#### G#### G A#### C####
A13c T C#### C#### T C#### G#### G G/A C/T
B1n Yes N C G T/C C G/C G/C G/A C/T
B1a T C G T#### C G/C G/C G/A C/T
B1b T C G T/C C G/C G/C G/A C/T
B1c T C G T/C C G/C G/C G/A C/T
B2n No N C C T C C G/C G/A C/T
B2a T C C T C C G/C G/A C/T
B2b T C C T C C G/C G/A C/T
B2c T C C T C C G/C G/A C/T
B6n Yes N C C T C G G/C G/A C/T
B6a T C C T C G G#### A#### T####
B6b T C C T C G G#### G/A C/T
B6c T C C T C G G#### A#### T####
B7n Yes N C C/G T C G G A C/T
B7a T C C/G T C G G A C/T
B7b T C C/G T C G G A C/T
B7c T C G#### T C G G A T####
B20n Yes N C G T/C C/T G/C G/C G/A C/T
B20a T C G T#### C#### G#### G#### A#### C/T
B20b T C G T#### C#### G#### G#### A#### C/T
B20c T C G T#### C#### G#### G#### G/A C/T
BCC, basal cell carcinoma; SNP, single nucleotide polymorphism.
#### represents LOH at certain SNP sites.
aSequence difference at any SNP site.
bN, normal tissue; T, tumor tissue.
cDatabase of Single Nucleotide Polymorphisms (dbSNP), National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD, USA)
(dbSNP accession). Build ID: rs574688 IVS1151C/G, rs1805155 1665T/C, rs2066836 1686C/T, rs2066829 IVS15+9G/C, rs2274692 IVS168G/C0,
rs2236406 IVS17+21G/A, and rs357564 3944C/T. Available at: http://www.ncbi.nlm.nih.gov/SNP/ and as described earlier (Heitzer et al., 2007).
dSingle letter indicates homozygosity for that base at a specific SNP locus.
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on patients with multiple sporadic
BCCs are consistent with our earlier
studies on multiple psoralen plus ultra-
violet light A-associated BCCs, in
which we found distinctly different
mutations in the PTCH gene (Heitzer
and Wolf, 2008) and/or p53 gene (Seidl
et al., 2001), which further supports
polyclonal origin of multiple BCCs. The
evidence that mutation and LOH of
PTCH are early events in BCC tumor-
igenesis makes it unlikely that the
differential mutations and LOH pattern
we detected in the BCCs may have
been due to subclone formation at later
time points during tumorigenesis (Asz-
terbaum et al, 1999). Thus, whereas
each BCC in a patient with multiple
lesions may be of monoclonal origin
(Asplund et al., 2005), multiple
lesions at anatomically different body
sites may not arise from the same
progenitor cell.
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